LifeMD Reports Third Quarter 2026 Results
LifeMD reported Q3 2026 revenue of $44.6 million, down about 7% year-over-year and below guidance, with a GAAP net loss from continuing operations of $0.11 per share. Adjusted EBITDA improved roughly $3.1 million sequentially to a loss of about $0.4 million, driven by a 34% sequential cut in selling and marketing expense, while active subscribers grew 13% YoY to approximately 350,000. However, the company cut full-year 2026 guidance to revenue of $188-191 million (from $205.5-212.5 million) and adjusted EBITDA of negative $12.6M to negative $10.6M (from negative $6.0M to breakeven).
Key figures
- Revenue
- 44625086
- Guidance
- FY26 revenue $188M-$191M (cut from $205.5M-$212.5M); FY26 adjusted EBITDA negative $12.6M to negative $10.6M (cut from negative $6.0M to breakeven); Q4 revenue $46M-$49M, adjusted EBITDA negative $4M to negative $2M
- Revenue Yoy
- -7%
- Cash
- 21921769
- Term loan
- 12500000
- Gross margin
- 82%
- Active subscribers
- 349744
- Subscriber growth yoy
- 13%
- Selling marketing expense
- 18500609
- Pharmacy shipment growth yoy
- 58.3%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.